Physician profile
Nicole A Link
NPI 1841582053
$4,042.01
in general payments reported to CMS, 2019-2025
27 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,008 · 2022: $848 · 2023: $679 · 2024: $583 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $986.81 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $399.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $383.76 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $278.05 | 2021-2025 | |
| Pfizer INC. | $269.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.44 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $194.84 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $170.44 | 2021-2024 | Evenity, Prolia, Repatha |
| Biohaven Pharmaceuticals, INC. | $123.78 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.56 | 2022 | |
| Abbott Laboratories | $106.95 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $97.04 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $95.67 | 2021-2023 | Xarelto |
| Nestle Healthcare Nutrition INC. | $77.11 | 2021-2022 | |
| Axsome Therapeutics, INC. | $76.98 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $76.30 | 2024-2025 | Tymlos |
| Boston Scientific Corporation | $56.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.91 | 2021-2025 | |
| Amarin Pharma, INC. | $39.10 | 2021 | |
| Exact Sciences Corporation | $37.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $32.04 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Phathom Pharmaceuticals, INC. | $30.97 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.08 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.77 | 2022 | |
| Lucid Diagnostics INC. | $13.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.